Julie Di Paolo
Senior Director, Immunology Therapeutic Area Lead Johnson & Johnson
Julie Di Paolo, PhD, is Senior Director and Immunology Scientific Innovation Lead at the Johnson & Johnson Boston Innovation Center, where she focuses on identifying and advancing external innovation and partnerships in immunology. Prior to joining Johnson & Johnson in 2022, Julie spent over a decade at Gilead Sciences, where she served as Executive Director and led research in inflammation biology, advancing programs targeting complex immune-mediated diseases. Earlier in her career, she held a series of scientific leadership roles at CGI Pharmaceuticals, building deep expertise in molecular biology and drug discovery. Julie began her scientific training with a PhD in Biochemical Pharmacology from Brown University followed by postdoctoral research at Yale School of Medicine.
Seminars
- The pharma icebreaker tables running in each track create introductions between biotech and pharma
- Two weeks out from the conference, pharma will review attending biotech and biotech will review attending pharma, with both making selection to meet with companies they haven’t scheduled meetings with yet through the One-to-One Partnering Portal
- With these selections, we will build a schedule of company rotations through each pharma’s table
- Join three tables, led by three pharma, for 30 minutes each. Mixed groups rather than 1-2-1s, hear how your peers pitch themselves whilst also getting facetime with pharma yourself, first thing on day one
- Which stage of development is most appealing in Immunology?
- What are the starting points, from a data package perspective, when it comes to assessing engagers or in vivo CAR-T?
- When evaluating an early-stage what level of data—whether safety, biomarkers, or efficacy—provides you with conviction that the program has true drug potential?
- Which diseases do you think are most promising for B-cell targeted therapies?
